- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02191852
Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers
July 16, 2014 updated by: Boehringer Ingelheim
A Pharmacokinetic Study on the Antioxidant Activity of Seresis® in the Skin: an Open, Uncontrolled, Non-randomized Intra-individual Pilot Trial in Healthy, Young Female Volunteers
Study to evaluate the total antioxidant capacity of Seresis® (with Thiobarbituric acid reactive substances (TBARS) assays)) in the skin; as well as in buccal mucosa cells (BMCs) and in plasma, compared to baseline values; furthermore to detect the quantitative enrichment of individual antioxidant compounds contained in the product and to investigate whether or not some of them accumulate in target tissues such as skin, BMCs and plasma
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy female volunteers between 18 and 30 years
- With skin type II or skin type III
- BMI < 25
- Non-smokers
- Volunteers who have given their written informed consent according to Good Clinical Practice (GCP) and local regulations
Exclusion Criteria:
- Any serious disorder that may interfere with her participation to the trial and evaluation of the safety of the test drug (e.g. liver and/or renal disease, hypervitaminosis A, psychic disorder, etc.), and/or treatment with chronic medication
- Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug that may influence the trial symptomatology and may interfere with evaluation of the safety of the test drug (e.g. vitamins and minerals supplementation)
- Relevant allergy or known hypersensitivity to the investigational drug or its excipients
- High performance sports
- Alcohol and drug abuse according to Diagnostic and Statistics Manual, Version IV (DSM-IV)
- Female volunteers in child-bearing age not using adequate means of birth control (contraceptive pills, Intrauterine devices (IUDs), sterilisation)
- Pregnancy and/or lactation
- Known abnormal values of the lab tests (if detected after enrolment, subjects will continue the treatment provided there are no medical objections)
- Abnormal values of low density lipoproteins (LDL) and triglycerides (TGL) levels in blood
- Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
- Specific dietary requirements that do not allow the volunteers to meet the dietary guidelines set out for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Seresis®
2 capsules per day for a period of 16 consecutive weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total antioxidant capacity in skin biopsies
Time Frame: Day 0, Day 112
|
Day 0, Day 112
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total antioxidant capacity in skin biopsies
Time Frame: Day 0, Day 56
|
Day 0, Day 56
|
Total antioxidant capacity in buccal mucosa cells (BMCs)
Time Frame: Day 0, 14, 28, 42, 56, 84, 112
|
Day 0, 14, 28, 42, 56, 84, 112
|
Total antioxidant capacity in plasma
Time Frame: Day 0, 14, 28, 42, 56, 84, 112
|
Day 0, 14, 28, 42, 56, 84, 112
|
Plasma levels of vitamin C and E and carotenoids
Time Frame: Day 0, 14, 28, 42, 56, 84, 112
|
Day 0, 14, 28, 42, 56, 84, 112
|
Levels of vitamin E and carotenoids in skin biopsies
Time Frame: Day 0, 56, 112
|
Day 0, 56, 112
|
Levels of vitamin E and carotenoids in BMCs
Time Frame: Day 0, 14, 28, 42, 56, 84, 112
|
Day 0, 14, 28, 42, 56, 84, 112
|
Number of subjects with adverse events
Time Frame: up to 119 days
|
up to 119 days
|
Assessment of tolerability by investigator on a 4-point scale
Time Frame: Day 112
|
Day 112
|
Assessment of tolerability by volunteers on a 4-point scale
Time Frame: Day 112
|
Day 112
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: up to 112 days
|
up to 112 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 1999
Primary Completion (Actual)
October 1, 1999
Study Registration Dates
First Submitted
July 14, 2014
First Submitted That Met QC Criteria
July 14, 2014
First Posted (Estimate)
July 16, 2014
Study Record Updates
Last Update Posted (Estimate)
July 17, 2014
Last Update Submitted That Met QC Criteria
July 16, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1135.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Lancaster UniversityRecruiting
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Seresis®
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina